The Division of Hematology and Hematologic Malignancies awarded pilot research grants of $40,000 to four faculty. We congratulate Drs. Paul Bray, Tim Luetkens, Doug Sborov and Mike Deininger for their selections as awardees. ... Read MoreInternal Medicine
Division of Hematology & Hematologic Malignancies
The scientific focus of our division is the study of blood and bone marrow in health and disease. Our physicians treat patients with blood cancer, such as leukemias and lymphomas; clotting disorders, such as hemophilia; and diseases of iron metabolism, such as hemochromatosis. Starting with Maxwell Wintrobe, one of the founding fathers of Hematology and the University of Utah Medical School, our division can look back at a long-standing tradition of excellence in research, clinical care and teaching.
John W. Athens Memorial Lecture
George Cartwright’s Legacy and the Division of Hematology and Hematologic Malignancies
The year 2017 marks the 100th birthday of Dr. George Cartwright who served as the Chief of the Hematology Division from 1950 to 1967 and as the Chair of the Department of Internal Medicine from 1967 to 1980. Our Division celebrates him as an eminent scholar and pioneer of his field who developed the science and clinical practice of Hematology much like a blueprint for other disciplines in medicine. Read more.
The Hematology Division enjoyed a group hike up to Dog Lake in the Wasatch Mountains on September 26. A recent snowfall resulted in a beautiful hike on a snow packed trail. ... Read MoreInternal Medicine
Congratulations to Drs. Mike Deininger and Thomas O'Hare for their receipt of a three year V Foundation Translational Grant award on Targeting SIRT5 in Acute Myeloid Leukemia. The V Foundation for Cancer Research was founded by legendary basketball coach Jim Valvano with the goal of achieving victory over cancer through research.... Read MoreInternal Medicine
Dr. Paul Shami and JSK Therapeutics were granted an award from the Small Business Innovation Research Program of the National Cancer Institute to conduct IND-enabling studies of their nitric oxide-generating drug JS-K. JS-K has shown efficacy in animal models of acute myeloid leukemia, multiple myeloma, non-small cell lung cancer and several other solid tumors. Completion of work conducted with this award will allow initiation of Phase I clinical trials of this first-in-class anti-cancer agent. Congratulations to Dr. Shami and his team for this Direct-to-Phase II SBIR award. ... Read MoreInternal Medicine
The 2017 Multiple Myeloma Symposium will be held at the Huntsman Cancer Institute on Saturday October 14, 2017 from 8:45 AM to 4 PM. Attendance is free, but registration is required. This symposium will provide an overview of recent developments in therapeutic approaches to myeloma. The program consists of local myeloma experts along with outside authorities. Dr. Adam Cohen from the University of Pennsylvania and Dr. Yi Lin from the Mayo Clinic are featured guest speakers and will address CAR T cell therapies.... Read MoreInternal Medicine
Congratulations to Dr. Josef Prchal on his selection by the American Society of Hematology for the prestigious 2017 Henry M. Stratton Medal. This award honors elite researchers in hematology research and Dr. Prchal has distinguished himself with his research into a range of disorders of erythrocytes including primary and secondary polycythemias. Dr. Prchal’s many innovations in the field include the description of the von Hippel-Lindau (VHL) mutation in recessive Chuvash familial polycythemia and elaboration on the pathobiology of erythropoietin receptor (EPOR) mutations in autosomal dominant familial polycythemia. His genetic investigations of acquired polycythemia vera led to the association of chromosome 9p abnormalities – where the JAK2 gene is located – with the disease. More recently, Dr. Prchal and his collaborators showed that Tibetans are protected from high altitude polycythemia as a result of a high altitude genetic adaptation due to variants of the EGLN1 and EPAS1 genes.... Read MoreInternal Medicine